Back 
Order now - $49 / month Go to Checkout 
*Prescription product require an online consultation with a dermatologist *Prescription
Rashesol® prescription rash relief
Choose how you want to order Oncoderm’s Rashesol® prescription rash relief is formulated to reduce extreme inflammation of the skin due to side effects from cancer treatment. Using a highly potent corticosteroid mixed in a naturally soothing, plant-powered base, this lightweight, non-greasy prescription-strength micro-mist spray was designed to calm, hydrate and heal large areas of the body.
Formulated by pharmacists and dermatologists for sensitive skin.
Active Ingredient: Clobetasol 0.05%
100% Fragrance-free. Non-comedogenic. Hypoallergenic.
Monthly Auto-Ship Program 
$49 / month
No-Drama Cancellations
$49 / month No-Drama Cancellations
One-Time Order Option $59
$59 
Formulated to relieve rashes
Using a highly potent corticosteroid in a plant-powered natural base, this lightweight, non-greasy, prescription-strength micro-mist spray was designed by doctors to hydrate and soothe large areas of the body.
Frequently Asked Questions
Are your prescriptions available in my state?
Currently, our prescription products are available to residents of California, Florida, New York and Texas with additional coverage coming soon.
What’s the difference between Oncoderm’s compounded medication and a prescription I can pick up at any pharmacy?
Mass-produced medication, while good for some, isn’t ideal for everyone. People undergoing cancer treatment typically have more sensitive immune systems, skin, hair, and nails than the general population. That’s why we started Oncoderm—to offer safe, effective solutions for people living with cancer at prices they could afford.
My doctor said that a rash from targeted therapy means the medicine is working. She prescribed a corticosteroid cream and an antibiotic, which have made it better. I’m happy that the rash has improved, but does this mean my targeted therapy is not working anymore?
With some of the so-called “targeted therapies” (bortezomib, cetuximab, erlotinib, gefitinib, and panitumumab), the development of a rash means the medication is having a greater anti-cancer effect. However, people who don’t develop a rash can still benefit from these medicines. For those who do develop a rash, treating it will not reduce the beneficial effect of the targeted treatment. In fact, managing the rash prevents discomfort and reduces the chance of having to change or stop your targeted therapy.
Choose how you want to order Order now - $49 / month Go to Checkout
Monthly Auto-Ship Program $49 / month
No-Drama Cancellations
$49 / month No-Drama Cancellations
One-Time Order Option $59
$59 You may also like